Surbhi Sidana, MD, discusses the ongoing trials that could expand the use of iberdomide into various combinations and ...
ESR1 mutations are acquired resistance alterations that can emerge during standard aromatase inhibitor therapy in patients ...
In this episode of The Moonlight Shift, Gina Mauro sits down with Herbert Lepor, MD, who serves as the Martin Spatz Chair of ...
After day 30, patients ≥65 years had greater transient physical-function worsening than younger patients, but age-related ...
In an interview with Targeted Oncologyâ„¢, Marcus Neubauer, MD, of The US Oncology Network, discusses system-level factors that ...
The FDA has approved rusfertide (Mimrylo) for adult patients with polycythemia vera (PV). 1 ...
Surbhi Sidana, MD, discusses the key aspects of iberdomide that make the CELMoD's FDA approval so significant for multiple ...
The FDA has approved ropeginterferon alfa-2b-njft (Besremi) for adults with essential thrombocythemia (ET), marking the first ...
A new CIRI2-CLL model uses MRD and clinical data to better predict CLL survival after fixed-duration therapy, enabling ...
Randomization of 172 induction-eligible adults across 9 US centers showed azacitidine–venetoclax improved EFS (HR, 0.57) ...
Shubham Pant, MD, MBBS, professor in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine at UT ...
Zanidatamab plus tislelizumab and chemotherapy reduced mortality risk by 28% versus trastuzumab plus chemotherapy, delivering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results